Evidence map›Paper›PMID 41991095›Full record

ReviewThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2026

Utility of donor-derived cell-free DNA testing after lung transplantation in the precision medicine era.

Brian C Keller, Sean Agbor-Enoh, Michael B Keller, Sravanthi Nandavaram, Adriana Zeevi, John F McDyer, Steven R Hays, S Samuel Weigt, John A Belperio, David M Sayah and 30 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Brian C KellerDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: bckeller@mgh.harvard.edu.
Sean Agbor-EnohGenomic Research Alliance for Transplantation (GRAfT), Bethesda, MD; Laboratory of Applied Precision Omics (APO), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Michael B KellerGenomic Research Alliance for Transplantation (GRAfT), Bethesda, MD; Division of Pulmonary Critical Care and Sleep Medicine. University of Maryland School of Medicine, Baltimore, MD; Division of Pulmonary and Critical Care Medicine, Baltimore VA Medical Center, Baltimore, MD.
Sravanthi NandavaramDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Adriana ZeeviDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.
John F McDyerThomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Steven R HaysDivision of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA.
S Samuel WeigtDivision of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA.
John A BelperioDivision of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA.
David M SayahDivision of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA.
Shambhu AryalGenomic Research Alliance for Transplantation (GRAfT), Bethesda, MD; Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA.
Jonathan B OrensGenomic Research Alliance for Transplantation (GRAfT), Bethesda, MD; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Anil J TrindadeDivision of Allergy Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
Ciara M ShaverDivision of Allergy Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.
Jonathan C YeungToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Shaf KeshavjeeToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Tereza MartinuToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Maria M CrespoDivision of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Jason D ChristieDivision of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Joshua M DiamondDivision of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; Respiratory Early Pipeline Unit, GSK, Collegeville, PA.
Selim M ArcasoyDivision of Pulmonary Allergy and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.
Rade TomicDivision of Pulmonary and Critical Care Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL.
Pablo G SanchezDivision of Thoracic Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL.
Derek E ByersDivision of Pulmonary and Critical Care Medicine. Washington University, St Louis, MO.
Scott M PalmerDivision of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Kieran HalloranDivision of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Alice L GrayDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO.
Daniel F DillingDivision of Pulmonary and Critical Care Medicine. Loyola University Chicago, Stritch School of Medicine, Maywood, IL.
Jake G NataliniDivision of Pulmonary and Critical Care Medicine, NYU Grossman School of Medicine, New York, NY.
Cynthia J GriesDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL.
Marie M BudevCleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH.
Nirmal S SharmaBaylor University School of Medicine, Baylor St. Lukes Medical Center, Houston, TX.
David J RossMedical Affairs in Organ Health, Natera Inc., Austin, TX.
Sangeeta BhoradeMedical Affairs in Organ Health, Natera Inc., Austin, TX; Transplant Center, Mayo Clinic, Rochester, MN.
Gerald J BerryGenomic Research Alliance for Transplantation (GRAfT), Bethesda, MD; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
Kiran K KhushDivision of Cardiovascular Medicine, Stanford Medicine, Stanford, CA.
Robert N WoodwardMedical Affairs, CareDx Inc., Brisbane, CA; Research and Development, CareDx Inc., Brisbane, CA.
Jennifer N GrayMedical Affairs, CareDx Inc., Brisbane, CA.
Christopher R EnsorMedical Affairs, CareDx Inc., Brisbane, CA.
Deborah J LevineDivision of Pulmonary and Critical Care Medicine, Stanford Medicine, Stanford, CA.

Funding

Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

Donor-derived cell-free DNA (dd-cfDNA) is a validated, highly sensitive, plasma molecular biomarker of allograft injury after solid organ transplantation. Robust experiences with dd-cfDNA testing after kidney and heart transplantation have generated interest in this biomarker within the lung transplantation (LTx) community. A growing body of evidence now provides increased insight into dd-cfDNA utility for molecular monitoring of lung allograft health after transplantation. The expanding understanding of lung allograft injury to appropriately frame the advancing role of dd-cfDNA in the evolution of the diagnostic approach after LTx is described. Performance characteristics of both laboratory-based shotgun-sequenced testing from the Genome Transplant Dynamics (GTD) and Genomic Research Alliance for Transplantation (GRAfT) consortia, as well as commercially available central lab-based algorithmic next-generation sequenced dd-cfDNA tests for lung transplant recipients (LTR) (AlloSure, CareDx and Prospera, Natera) are described. Kinetics of dd-cfDNA in LTRs over time, in multiple different clinical scenarios, from several investigator groups are aggregated. Phenotypes of lung allograft injury, such as acute lung allograft dysfunction and associated dd-cfDNA patterns and performance, are identified in alignment with established definitions and evolving molecular injury insights. Certain patterns of molecular injury that may predict long-term outcomes including chronic lung allograft dysfunction and mortality are examined. Lastly, clinical approaches to testing and interpretation of dd-cfDNA results in LTRs, a practical approach to using dd-cfDNA, and a rational framework for interpreting dd-cfDNA results in LTRs are presented.

Indexed as

Cell-Free Nucleic AcidsLung TransplantationPrecision MedicineTissue DonorsBiomarkersHumansBiomarkersCell-Free Nucleic AcidsDonor-derived cell-free DNA (dd-cfDNA)Lung allograft dysfunctionLung transplantationMolecular injuryPrecision medicine

Identifiers

PMID41991095
PMCPMC13310367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.